Dainippon Of Japan To Establish U.S. Holding Company
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma plans to establish a holding company in the United States to improve on the time it takes to get its drugs through the U.S. FDA approval process. The U.S. firm also is intended to serve as a sales base for its SM-13496 (lurasidone) drug for treating schizophrenia, which, although it is still in clinical trials, the company plans to have on the market as early as 2011. A Phase III trial of the drug has shown the drug to be far more effective than placebos in treating acute schizophrenia. (Click here for more - a subscription may be required